Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | LONP1 | P36776 | 9/20 | 0.61 |
| ▸ | PSMB5 | P28074 | 9/20 | 0.61 |
| ▸ | PSMB8 | P28062 | 8/20 | 0.61 |
| ▸ | PSMB9 | P28065 | 8/20 | 0.61 |
| ▸ | PSMB6 | P28072 | 8/20 | 0.61 |
| ▸ | PSMB10 | P40306 | 8/20 | 0.61 |
| ▸ | PSMB11 | A5LHX3 | 7/20 | 0.61 |
| ▸ | PSMA7 | O14818 | 7/20 | 0.61 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.61 |
| ▸ | PSMA1 | P25786 | 7/20 | 0.61 |
| ▸ | PSMA2 | P25787 | 7/20 | 0.61 |
| ▸ | PSMA3 | P25788 | 7/20 | 0.61 |
| ▸ | PSMA4 | P25789 | 7/20 | 0.61 |
| ▸ | PSMA5 | P28066 | 7/20 | 0.61 |
| ▸ | PSMB4 | P28070 | 7/20 | 0.61 |
| ▸ | PSMB3 | P49720 | 7/20 | 0.61 |
| ▸ | PSMB2 | P49721 | 7/20 | 0.61 |
| ▸ | PSMA6 | P60900 | 7/20 | 0.61 |
| ▸ | PSMA8 | Q8TAA3 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095238 | 1.00 | CTSL (0.64) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL16492912 | 0.85 | PSMB5 (0.78) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL21558117 | 0.85 | PSMB5 (0.78) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL18848799 | 0.85 | PSMB5 (0.78) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL16362648 | 0.85 | PSMB5 (0.78) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL464470 | 0.85 | PSMB5 (0.78) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL25003548 | 0.85 | CTSL (0.69) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL13078869 | 0.84 | CTSL (0.71) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL535687 | 0.84 | LONP1 (0.71) | CTSLLONP1PSMB5PSMB8PSMB9 | |
| SCHEMBL535688 | 0.84 | LONP1 (0.71) | CTSLLONP1PSMB5PSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180093-B2 | Stable bortezomib formulations | INNOPHARMA, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9180093-B2 | Stable bortezomib formulations | INNOPHARMA, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9107821-B2 | Stable bortezomib formulations | INNOPHARMA, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9107821-B2 | Stable bortezomib formulations | INNOPHARMA, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20120322763-A1 | Stable Bortezomib Formulations | INNOPHARMA, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322763-A1 | Stable Bortezomib Formulations | INNOPHARMA, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322762-A1 | Stable Bortezomib Formulations | INNOPHARMA, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322762-A1 | Stable Bortezomib Formulations | INNOPHARMA, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8263578-B2 | Stable bortezomib formulations | INNOPHARMA, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263578-B2 | Stable bortezomib formulations | INNOPHARMA, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120172808-A1 | Stable Bortezomib Formulations | INNOPHARMA, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172808-A1 | Stable Bortezomib Formulations | INNOPHARMA, LLC (US) | 2012-07-05 | — | — | US | disclosed |
| US-20100226597-A1 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322763-A1 | Stable Bortezomib Formulations | PSMB10, PSMB2, PSMC6 | CTSL 2029/4885LONP1 1346/4885PSMB5 23/4885 |
| US-20120322762-A1 | Stable Bortezomib Formulations | PSMB10, PSMB2, PSMC6 | CTSL 2029/4885LONP1 1346/4885PSMB5 23/4885 |
| US-20100226597-A1 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | PSMC1, PSMB4, PSMB1 | CTSL 723/4885LONP1 505/4885PSMB5 10/4885 |
| US-20120172808-A1 | Stable Bortezomib Formulations | PSMB10, PSMB2, PSMC6 | CTSL 2029/4885LONP1 1346/4885PSMB5 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.